IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental tablet called HSK39297 in 370 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and slow down kidney function decline over 36 to 48 weeks. Participants will be randomly assigned to receiv…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 20:04 UTC
-
Experimental CAR-T therapy targets lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for kidney patients: early budesonide may slow IgA nephropathy
Disease control Recruiting nowThis study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults with recent diagnosis and high protein in urine will take the drug for 12 months. Researchers will measure changes in protein levels and kidney fun…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug ADX-038 aims to control kidney disease in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (like IgA nephropathy and C3 glomerulopathy). The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disea…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for kidney patients: avacopan combo trial targets crescentic IgA nephropathy
Disease control Recruiting nowThis study tests whether the drug avacopan, combined with a low-dose steroid, can help people with a severe form of IgA nephropathy (a kidney disease). The goal is to reduce protein in the urine and protect kidney function. About 16 adults with active disease and high risk of wor…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New kidney drug trial aims to control IgA nephropathy Long-Term
Disease control Recruiting nowThis study tests a new tablet, HSK39297, for long-term safety and effectiveness in people with IgA nephropathy, a kidney disease. About 73 adults who completed a prior study will take the drug daily, with a possible dose increase if needed. The main goal is to check for side effe…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:09 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New shot could slow kidney damage in IgA patients
Disease control Recruiting nowThis study tests a new injection called RG002C0106 for people with IgA nephropathy, a kidney disease. About 30 adults aged 18 to 65 will receive either the drug or a placebo to see if it safely reduces protein in the urine, a sign of kidney damage. The goal is to control the dise…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
New pill could tame protein leak in kidney disease
Disease control Recruiting nowThis study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgAN) that cause protein to leak into urine. Participants take two capsules twice daily for 52 weeks. The goal is to see if the drug safely reduces protein levels a…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 03, 2026 12:05 UTC
-
New study aims to uncover why some kidney patients Don't get better
Knowledge-focused Recruiting nowThis study follows 800 adults with IgA nephropathy, a kidney disease, to see how well current treatments work in everyday medical practice. Researchers want to understand why some patients still have protein in their urine or worsening kidney function despite standard care. The g…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC